My.vectrada.com

There has been consistent recognition of the need for more objective, precise markers of rheumatoid arthritis (RA) disease progression risk to complement clinical assessments. Recent publications are indicating progress towards development of such tests...

Merck & Co. Inc.’s Feb. 5 announcement that it is collaborating with three companies to test various combinations of its investigational oncology compound MK-3475 with their drugs highlights the extent to which the big pharma is committed to...

Myriad Genetics Inc. will buy South San Francisco's Crescendo Bioscience Inc. for $270 million cash, the companies said Tuesday. The deal positions 130-employee Crescendo — the developer of Vectra DA, a test to help rheumatoid arthritis patients...

MANHASSET, NY--(Marketwired - July 05, 2016) - Clinical data published in Proceedings of the National Academy of Sciences (PNAS) Delivery of electric current to vagus nerve could provide more treatment options and aLTErnatives to costly immunosuppressive...

Data Show Vectra DA is Better Predictor of Joint Damage in RA Patients SALT LAKE CITY, Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (MYGN), today presented new...